BCEL Atreca, Inc.

12.58-0.77 (-5.77%)
Close: December 13, 2019

Quote

Previous Close
$12.58
Day Range
$12.52-$13.89
52 Week Range
$9.51-$23.65
Volume
77,481
Avg Volume
126,709
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$351.75M
Enterprise Value (EV)
$468.59M
PE Ratio
-
EV/EBITDA
-12.60
Price/Sales
-
Price/Book
-
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$37.20M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
2/26/2020 (74 days)
Debt to Equity
-226%
Debt
$231.35M
Cash
$114.50M
Net Debt
$116.84M

Performance

Beta
-0.66
200 Day Moving Avg
$13.71
50 Day Moving Avg
$11.32
52 Week Change
-30.30%
YTD Change
-36.07%
1 Month Change
17.68%
3 Month Change
0.88%
6 Month Change
-30.30%
1 Year Change
-30.30%
2 Year Change
-26.04%
5 Year Change
-26.04%

Share Count

Shares Outstanding
22.0M
Float
20.0M
Restricted Shares
2.1M
Restricted Shares, %
9.37%

Atreca, Inc. Company Details

Sector: Commercial Services

Industry: Miscellaneous Commercial Services

CEO: John A. Orwin

Website: http://www.atreca.com

Description: Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.

Employees: 85